260 related articles for article (PubMed ID: 36016407)
1. Baculovirus Display of Varicella-Zoster Virus Glycoprotein E Induces Robust Humoral and Cellular Immune Responses in Mice.
Xue W; Li T; Zhang S; Wang Y; Hong M; Cui L; Wang H; Zhang Y; Chen T; Zhu R; Chen Z; Zhou L; Zhang R; Cheng T; Zheng Q; Zhang J; Gu Y; Xia N; Li S
Viruses; 2022 Aug; 14(8):. PubMed ID: 36016407
[TBL] [Abstract][Full Text] [Related]
2. Efficient induction of cell-mediated immunity to varicella-zoster virus glycoprotein E co-lyophilized with a cationic liposome-based adjuvant in mice.
Wui SR; Kim KS; Ryu JI; Ko A; Do HTT; Lee YJ; Kim HJ; Lim SJ; Park SA; Cho YJ; Kim CG; Lee NG
Vaccine; 2019 Apr; 37(15):2131-2141. PubMed ID: 30827737
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of glycoprotein E subunit and live attenuated varicella-zoster virus vaccines formulated with a single-strand RNA-based adjuvant.
Lee SJ; Park HJ; Ko HL; Lee JE; Lee HJ; Kim H; Nam JH
Immun Inflamm Dis; 2020 Jun; 8(2):216-227. PubMed ID: 32167678
[TBL] [Abstract][Full Text] [Related]
4. Breadth and Functionality of Varicella-Zoster Virus Glycoprotein-Specific Antibodies Identified after Zostavax Vaccination in Humans.
Sullivan NL; Reuter-Monslow MA; Sei J; Durr E; Davis CW; Chang C; McCausland M; Wieland A; Krah D; Rouphael N; Mehta AK; Mulligan MJ; Pulendran B; Ahmed R; Vora KA
J Virol; 2018 Jul; 92(14):. PubMed ID: 29743372
[TBL] [Abstract][Full Text] [Related]
5. Truncated glycoprotein E of varicella-zoster virus is an ideal immunogen for Escherichia coli-based vaccine design.
Chen T; Sun J; Zhang S; Li T; Liu L; Xue W; Zhou L; Liang S; Yu Z; Zheng Q; Yu H; Cheng T; Zhang J; Gu Y; Li S; Xia N
Sci China Life Sci; 2023 Apr; 66(4):743-753. PubMed ID: 36790656
[TBL] [Abstract][Full Text] [Related]
6. LNP-CpG ODN-adjuvanted varicella-zoster virus glycoprotein E induced comparable levels of immunity with Shingrix™ in VZV-primed mice.
Luan N; Cao H; Wang Y; Lin K; Liu C
Virol Sin; 2022 Oct; 37(5):731-739. PubMed ID: 35671982
[TBL] [Abstract][Full Text] [Related]
7. Enhanced Potency and Persistence of Immunity to Varicella-Zoster Virus Glycoprotein E in Mice by Addition of a Novel BC02 Compound Adjuvant.
Li J; Fu L; Yang Y; Wang G; Zhao A
Vaccines (Basel); 2022 Mar; 10(4):. PubMed ID: 35455278
[TBL] [Abstract][Full Text] [Related]
8. Immune Responses to Varicella-Zoster Virus Vaccines.
Levin MJ; Weinberg A
Curr Top Microbiol Immunol; 2023; 438():223-246. PubMed ID: 35102438
[TBL] [Abstract][Full Text] [Related]
9. Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults.
Chlibek R; Pauksens K; Rombo L; van Rijckevorsel G; Richardus JH; Plassmann G; Schwarz TF; Catteau G; Lal H; Heineman TC
Vaccine; 2016 Feb; 34(6):863-8. PubMed ID: 26432913
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity in Mice Immunized with Recombinant Adenoviruses Expressing Varicella-Zoster Virus Envelope Glycoprotein E.
Zheng Y; Huang L; Ding H; Xu H; Shu R; Yu J; Peng X; Fu Y; He J
Viruses; 2023 Nov; 15(12):. PubMed ID: 38140528
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of Varicella Zoster Virus DNA Vaccines Encoding Glycoprotein E and Immediate Early Protein 63 in Mice.
Liu J; Lin J; Cai L; Sun J; Ding X; Wang C; Wu Y; Gao X; Su W; Jiang C
Viruses; 2022 Jun; 14(6):. PubMed ID: 35746685
[TBL] [Abstract][Full Text] [Related]
12. Herpes Zoster Vaccines.
Harbecke R; Cohen JI; Oxman MN
J Infect Dis; 2021 Sep; 224(12 Suppl 2):S429-S442. PubMed ID: 34590136
[TBL] [Abstract][Full Text] [Related]
13. [Herpes zoster and subunit vaccine].
Imafuku S
Uirusu; 2021; 71(1):45-54. PubMed ID: 35526994
[TBL] [Abstract][Full Text] [Related]
14. Herpes Zoster and Its Prevention by Vaccination.
Johnson RW; Levin MJ
Interdiscip Top Gerontol Geriatr; 2020; 43():131-145. PubMed ID: 32305975
[TBL] [Abstract][Full Text] [Related]
15. Protocol of a randomised controlled trial characterising the immune responses induced by varicella-zoster virus (VZV) vaccination in healthy Kenyan women: setting the stage for a potential VZV-based HIV vaccine.
Perciani CT; Jaoko W; Walmsley S; Farah B; Mahmud SM; Ostrowski M; Anzala O; Team KI; MacDonald KS
BMJ Open; 2017 Sep; 7(9):e017391. PubMed ID: 28939581
[TBL] [Abstract][Full Text] [Related]
16. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine.
Weinberg A; Zhang JH; Oxman MN; Johnson GR; Hayward AR; Caulfield MJ; Irwin MR; Clair J; Smith JG; Stanley H; Marchese RD; Harbecke R; Williams HM; Chan IS; Arbeit RD; Gershon AA; Schödel F; Morrison VA; Kauffman CA; Straus SE; Schmader KE; Davis LE; Levin MJ;
J Infect Dis; 2009 Oct; 200(7):1068-77. PubMed ID: 19712037
[TBL] [Abstract][Full Text] [Related]
17. Identification and Characterization of CD4
Voic H; de Vries RD; Sidney J; Rubiro P; Moore E; Phillips E; Mallal S; Schwan B; Weiskopf D; Sette A; Grifoni A
J Virol; 2020 Nov; 94(24):. PubMed ID: 32999027
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity generated by mRNA vaccine encoding VZV gE antigen is comparable to adjuvanted subunit vaccine and better than live attenuated vaccine in nonhuman primates.
Monslow MA; Elbashir S; Sullivan NL; Thiriot DS; Ahl P; Smith J; Miller E; Cook J; Cosmi S; Thoryk E; Citron M; Thambi N; Shaw C; Hazuda D; Vora KA
Vaccine; 2020 Aug; 38(36):5793-5802. PubMed ID: 32703745
[TBL] [Abstract][Full Text] [Related]
19. Th1 memory differentiates recombinant from live herpes zoster vaccines.
Levin MJ; Kroehl ME; Johnson MJ; Hammes A; Reinhold D; Lang N; Weinberg A
J Clin Invest; 2018 Oct; 128(10):4429-4440. PubMed ID: 30024861
[TBL] [Abstract][Full Text] [Related]
20. The herpes zoster subunit vaccine.
Cunningham AL
Expert Opin Biol Ther; 2016; 16(2):265-71. PubMed ID: 26865048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
